Double-blind, Placebo-controlled, Proof-of-concept Trial of Bexarotene Xin Moderate Alzheimer's Disease

Overview

Journal Alzheimers Res Ther

Date 2016 Jan 30

PMID 26822146

Citations 91

Authors

Jeffrey L Cummings

Kate Zhong

Jefferson W Kinney

Chelcie Heaney

Joanne Moll-Tudla

Abhinay Joshi

Michael Pontecorvo

Michael DeVous

Anne Tang

James Bena

Affiliations

Soon will be listed here.

Abstract

Background: We assessed the impact of retinoid X receptor (RXR) agonist bexarotene on brain amyloid measured by amyloid imaging in patients with Alzheimer's disease (AD) in a proof-of-concept trial.

Methods: Twenty patients with AD [Mini Mental State Examination (MMSE) score 10-20 inclusive] with positive florbetapir scans were randomized to receive 300 mg of bexarotene or placebo for 4 weeks. The amyloid imaging result was the primary outcome. Whole-population analyses and prespecified analyses by genotype [apolipoprotein E ε4 (ApoE4) carriers and ApoE4 noncarriers] were conducted. Secondary outcomes included scores on the Alzheimer's Disease Assessment Scale-Cognitive subscale, Alzheimer's Disease Cooperative Study-Activities of Daily Living scale, MMSE, Clinical Dementia Rating scale, and Neuropsychiatric Inventory. Serum amyloid-β (Aβ) peptide sequences Aβ1-40 and Aβ1-42 measurements were collected as biomarker outcomes.

Results: There was no change in the composite or regional amyloid burden when all patients were included in the analysis. ApoE4 noncarriers showed a significant reduction in brain amyloid on the composite measure in five of six regional measurements. No change in amyloid burden was observed in ApoE4 carriers. There was a significant association between increased serum Aβ1-42 and reductions in brain amyloid in ApoE4 noncarriers (not in carriers). There were significant elevations in serum triglycerides in bexarotene-treated patients. There was no consistent change in any clinical measure.

Conclusions: The primary outcome of this trial was negative. The data suggest that bexarotene reduced brain amyloid and increased serum Aβ1-42 in ApoE4 noncarriers. Elevated triglycerides could represent a cardiovascular risk, and bexarotene should not be administered outside a research setting. RXR agonists warrant further investigations as AD therapies.

Trial Registration: ClinicalTrials.gov identifier NCT01782742 . Registered 29 January 2013.

Citing Articles

Comparative Evaluation and Profiling of Chemical Tools for the Nuclear Hormone Receptor Family 2.

Lewandowski M, Busch R, Marschner J, Merk D ACS Pharmacol Transl Sci. 2025; .

PMID: 40046426 PMC: 7617459. DOI: 10.1021/acsptsci.4c00719.

Cellular senescence induced by cholesterol accumulation is mediated by lysosomal ABCA1 in APOE4 and AD.

Wang S, Li B, Li J, Cai Z, Hugo C, Sun Y Mol Neurodegener. 2025; 20(1):15.

PMID: 39901180 PMC: 11792374. DOI: 10.1186/s13024-025-00802-7.

Recent advancements in the therapeutic approaches for Alzheimer's disease treatment: current and future perspective.

Sharma A, Rudrawar S, Bharate S, Jadhav H RSC Med Chem. 2025; 16(2):652-693.

PMID: 39790124 PMC: 11707861. DOI: 10.1039/d4md00630e.

Prevalence of ApoE Alleles in a Spanish Population of Patients with a Clinical Diagnosis of Alzheimer's Disease: An Observational Case-Control Study.

Bello-Corral L, Seco-Calvo J, Molina Fresno A, Gonzalez A, Llorente A, Fernandez-Lazaro D Medicina (Kaunas). 2025; 60(12.

PMID: 39768823 PMC: 11679489. DOI: 10.3390/medicina60121941.

New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease.

Cao Y, Zhao L, Chen Z, Li S Front Neurosci. 2024; 18:1430465.

PMID: 39323915 PMC: 11422391. DOI: 10.3389/fnins.2024.1430465.

References

Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M . An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S33-9. View

Chiang K, Koo E . Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol. 2014; 54:381-405. DOI: 10.1146/annurev-pharmtox-011613-135932. View

. 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 2015; 11(3):332-84. DOI: 10.1016/j.jalz.2015.02.003. View

Cummings J, Mega M, Gray K, Carusi D, Gornbein J . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44(12):2308-14. DOI: 10.1212/wnl.44.12.2308. View

Veeraraghavalu K, Zhang C, Miller S, Hefendehl J, Rajapaksha T, Ulrich J . Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science. 2013; 340(6135):924-f. DOI: 10.1126/science.1235505. View

Tesseur I, Lo A, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M . Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science. 2013; 340(6135):924-e. DOI: 10.1126/science.1233937. View

Bohm C, Chen F, Sevalle J, Qamar S, Dodd R, Li Y . Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways. Mol Cell Neurosci. 2015; 66(Pt A):3-11. PMC: 4503820. DOI: 10.1016/j.mcn.2015.02.016. View

Cummings J . Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 2011; 7(3):e13-44. DOI: 10.1016/j.jalz.2010.06.004. View

Balducci C, Paladini A, Micotti E, Tolomeo D, La Vitola P, Grigoli E . The Continuing Failure of Bexarotene in Alzheimer's Disease Mice. J Alzheimers Dis. 2015; 46(2):471-82. DOI: 10.3233/JAD-150029. View

10.

Price A, Xu G, Siemienski Z, Smithson L, Borchelt D, Golde T . Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science. 2013; 340(6135):924-d. DOI: 10.1126/science.1234089. View

11.

Fitz N, Cronican A, Lefterov I, Koldamova R . Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science. 2013; 340(6135):924-c. PMC: 4086452. DOI: 10.1126/science.1235809. View

12.

Dubois B, Feldman H, Jacova C, Hampel H, Molinuevo J, Blennow K . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014; 13(6):614-29. DOI: 10.1016/S1474-4422(14)70090-0. View

13.

Hurd M, Martorell P, Delavande A, Mullen K, Langa K . Monetary costs of dementia in the United States. N Engl J Med. 2013; 368(14):1326-34. PMC: 3959992. DOI: 10.1056/NEJMsa1204629. View

14.

Cramer P, Cirrito J, Wesson D, Lee C, Karlo J, Zinn A . ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 2012; 335(6075):1503-6. PMC: 3651582. DOI: 10.1126/science.1217697. View

15.

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

16.

Lowenthal J, Hull S, Pearson S . The ethics of early evidence--preparing for a possible breakthrough in Alzheimer's disease. N Engl J Med. 2012; 367(6):488-90. PMC: 3469579. DOI: 10.1056/NEJMp1203104. View

17.

LaFerla F . Preclinical success against Alzheimer's disease with an old drug. N Engl J Med. 2012; 367(6):570-2. DOI: 10.1056/NEJMcibr1204890. View

18.

Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G . Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014; 13(6):419-31. DOI: 10.1038/nrd4309. View

19.

Farol L, Hymes K . Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004; 4(2):180-8. DOI: 10.1586/14737140.4.2.180. View

20.

Koldamova R, Fitz N, Lefterov I . ATP-binding cassette transporter A1: from metabolism to neurodegeneration. Neurobiol Dis. 2014; 72 Pt A:13-21. PMC: 4302328. DOI: 10.1016/j.nbd.2014.05.007. View